David Maki has been associated with life science organizations for over 35 years, and he is the managing partner of Altitude Life Science Ventures, an early stage venture capital firm. Prior to co-founding Altitude in 2003, he served as a partner with Perennial Ventures and as a vice president with Tredegar Investments. From 1987 to 1999, he served as a partner at the intellectual property firm of Seed and Berry (now Seed IP Law), where he focused on strategic planning for healthcare companies. During the latter portion of his 17-year tenure at the firm, Mr. Maki also served in the roles of managing partner and financial partner. Under his leadership as Senior Partner in the Biotechnology Group, the firm represented over 60 healthcare companies. He currently serves as a director on the board of Omniome, and he has previously served on the board of directors of Pulmatrix, Xcyte Therapies, Ceptyr and Advanced Imaging Technologies, and as chairman of the board of the Infectious Disease Research Institute.